Given that current Dex vaccines have been observed to have limited clinical effects and minor antigen-specific T-cell function in clinical trials, we proposed to generate RAE-1γ-expressing CML-specific Dex by pulsing DCs with RAE-1γ-enriched CML cell lysates; these Dex in turn will prime T cells and NK cells to produce strong anti-CML efficacy via the NKG2D pathway. This evidence concerns the gene KLRK1 and chronic myelogenous leukemia, BCR-ABL1 positive.